MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202511131819 A) filed by IIMT College of Pharmacy, Greater Noida, Uttar Pradesh, on Dec. 25, 2025, for 'liposomal nanoparticles for targeted delivery of anti-cancer agents and method thereof.'
Inventor(s) include Nakul Gupta; Bhakti Pandey; Shweta Sharma; and Ravi Rawat.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "The present disclosure provides liposomal nanoparticles for targeted delivery of anti-cancer agents. Each nanoparticle includes a liposomal core encapsulating an anti-cancer agent, which may be doxorubicin or paclitaxel, a targeting moiety attached to the surface of the liposomal core that binds specifically to tumor cells, and a biocompatible polymer such as polyethylene glycol to reduce recognition by the immune system. The liposomal core contains phospholipids selected from phosphatidylcholine, phosphatidylethanolamin, and phosphatidylserine. The nanoparticles are administered to a patient in need of cancer treatment, where they bind to tumor cells and release the anti-cancer agent at the tumor site in a controlled manner. This targeted delivery reduces systemic side effects and enhances therapeutic efficacy. The method is applicable to various cancers, including breast, lung, liver, and colon cancers, providing a precise, efficient, and biocompatible treatment strategy."
Disclaimer: Curated by HT Syndication.
